Abstract: Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.

Abstract: This disclosure provides compounds and compositions useful for treating spirochete diseases such as Lyme disease as well as baits containing the compounds.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Abstract: Novel compounds and analogues that exhibit antimicrobial activity—particularly against Gram-negative pathogens—are producible from bacterial isolate Photorhabdus australis DSM 17609 and some related bacterial species of the genus. Pharmaceutical compositions containing the novel compound and its analogues are useful for treating or preventing a bacterial infection. Compounds in accordance herewith include ribosomally produced and post-translationally modified cyclic peptides useful for the treatment, amelioration, and prevention of bacterial infections by Gram-negative pathogens, in addition to other indications.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Abstract: Embodiments of the present invention relate to a novel compound of Formula (I) or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria.

Abstract: The present disclosure is directed towards a method of treating a disease or condition associated with gut inflammation. The present disclosure comprises administering, to a patient in need thereof, a composition comprising oxygen-scavenging membrane fragments or membrane vesicles. In some embodiments, membrane vesicles are derived from bacteria. In some embodiments, membrane vesicles are derived from the cytoplasmic membranes of Escherichia coli, Salmonella typhimurium, Gluconobacter oxydans, Pseudomonas aeruginosa, or Acetobacter.

Abstract: Disclosed herein are compositions and methods for the treatment and/or detection of diseases such as, but not limited to Lyme disease, Lyme disease-related disorders including post-treatment Lyme disease syndrome (PTLDS), chronic Lyme disease (CLD) and/or inflammation.

Abstract: Embodiments of the present invention relate to a novel compound of Formula (I) or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Abstract: A hybrid flow meter includes a fluid obstruction element, two or more pressure ports, a support member, and a vortex shedding sensor system. The fluid obstruction element is placed in a fluid conduit, and includes a cone-shaped member having a pair of frusto-conical portions joined at their larger ends. The pressure ports provide measurement points for measuring a change in fluid pressure caused by the fluid obstruction element. The support member for the fluid obstruction element extends across the entire diameter of the fluid conduit, and is shaped to function as a vortex shedding bluff body, holds in place the fluid obstruction element. The vortex shedding sensor system provides a measurement point for measuring a vortex shedding frequency generated by the support member.

Abstract: The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Abstract: Assays for compounds having a desired biological activity against one but not both of a pair of microorganism species utilize separately detectable labels. The first and second microorganisms are different from each other, the first microorganisms exhibit a first detectable label, the second microorganisms exhibit a second detectable label different from the first detectable label, and neither of the labels interferes with detection of the other label. In various embodiments, the first and second microorganisms are incubated with a candidate compound or a producer thereof The different labels permit isolation of microorganisms exhibiting one of the labels but not the other, indicating the desired activity, and the compound responsible for this differential response is isolated.

Abstract: The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.

Abstract: This invention provides, among other things, compounds useful for treating spirochete diseases such as Lyme disease, as well as pharmaceutical formulations and/or environmental baits containing such compounds.

Abstract: Embodiments of the present invention relate to a novel compound of Formula (I) or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.